BFS
IBRX icon

Bare Financial Services’s ImmunityBio IBRX Stock Holding History

Bare Financial Services’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$665 Sell
76
-53
-41% -$401 ﹤0.01% 1548
2026
Q1 		$989 Buy
+129
New +$883 ﹤0.01% 1253

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bare Financial Services's IBRX Position: Q2 2026 in Review

Bare Financial Services reduced its ImmunityBio (IBRX) stake by 41% in Q2 2026, selling an estimated $401 and leaving 76 shares worth $665. The position accounts for ﹤0.01% of the portfolio, ranked #1548.

Bare Financial Services first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $989 in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Bare Financial Services held 76 shares of ImmunityBio worth $665 as of Q2 2026.
  • Bare Financial Services sold 53 ImmunityBio shares in Q2 2026, an estimated $401.
  • ImmunityBio made up ﹤0.01% of Bare Financial Services's portfolio in Q2 2026, its #1548 holding.
  • Bare Financial Services first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
  • Bare Financial Services's ImmunityBio position peaked at $989 in Q1 2026.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Bare Financial Services's 13F filing for Q2 2026, filed 27 Jul 2026.